CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,832 enrolled
Drug / intervention
not applicable (observational study)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02533960
NCT02533960N/ACompleted

Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime

University Hospital Heidelberg·observational·Posted Aug 27, 2015·Updated Jun 27, 2023

In Brief

An observational study evaluating not applicable (observational study) for Ischemic Stroke and 4 related conditions. Completed, enrolled 3,832 participants across 1 site.

Detailed Summary

The Registry of Acute Stroke Under Novel Oral Anticoagulants-Prime (RASUNOA-Prime), an investigator-initiated study, is a German multicenter, prospective, observational registry. It is performed at about 50 certified stroke-units and supported by an unrestricted grant from different pharmaceutical companies to the Heidelberg University Hospital. RASUNOA-Prime is designed to assess the emergency management of acute ischemic and hemorrhagic stroke patients with atrial fibrillation (AF) under different anticoagulation schemes pre stroke: Non-vitamin K antagonist oral anticoagulants (NOAC), Vitamin K antagonists (VKA), and no anticoagulation.

Study Details

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 27, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 1, 2021
Study CompletionJun 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 10.8 years ago

Interventions

not applicable (observational study)other

Observational study without study related intervention.